http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Crinetics+Pharmaceutical++For%3A+Jul+21/26796066.html si-local-file:///var/storage/secattach/20260721/26796066.html http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Crinetics+Pharmaceutical++For%3A+Jul+21/26796066.html Tue, 21 Jul 2026 16:31:00 -0400 CRNX O.38517645 http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Crinetics+Pharmaceutical++For%3A+Jul+21/26796066.html si-local-file:///var/storage/secattach/20260721/26796066.html http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Crinetics+Pharmaceutical++For%3A+Jul+21/26796066.html Tue, 21 Jul 2026 16:31:00 -0400 CRNX O.38517645 http://www.streetinsider.com/Press+Releases/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Crinetics+Pharmaceuticals%2C+Inc.+is+obtaining+a+Fair+Price+for+Public+Shareholders/26792257.html <p>MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex.</p> <p>Click <a href="https://www.globenewswire.com/Tracker?data=foMAkBh424rkltyyEHFk-BbmmRKYTuUS1ELCK4rPUffg6yJPJhh7L3weTk9-FxQlaPRgSRm1ev1CeV1Kp_vWEzRnKb6ahguUmpu1ZiyvYD5VLGRn-us3Hkn06jce0VHh" rel="nofollow" target="_blank">here</a> to learn how to join our investigation and obtain additional information or contact us at <a href="https://www.globenewswire.com/Tracker?data=8UMWmk6-yDqO_o0cdnAEOF8LreIkC2QRzSZ4SArFVM_dXM7a78mEuY3GwKfmMFimGWeRkNzhLvCtfkDGSej6H6zf9yckz3H67tPGfPyjXDM=" rel="nofollow" target="_blank">gademi@ademilaw.com</a> or toll-free: 866-264-3995. There is no cost or obligation to you.</p> <p>Crinetics shareholders will receive $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. Crinetics insiders will http://www.streetinsider.com/Press+Releases/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Crinetics+Pharmaceuticals%2C+Inc.+is+obtaining+a+Fair+Price+for+Public+Shareholders/26792257.html Tue, 21 Jul 2026 07:37:44 -0400 CRNX http://www.streetinsider.com/Globe+Newswire/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Crinetics+Pharmaceuticals%2C+Inc.+is+obtaining+a+Fair+Price+for+Public+Shareholders/26792257.html <p>MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex.</p> <p>Click <a href="https://www.globenewswire.com/Tracker?data=foMAkBh424rkltyyEHFk-BbmmRKYTuUS1ELCK4rPUffg6yJPJhh7L3weTk9-FxQlaPRgSRm1ev1CeV1Kp_vWEzRnKb6ahguUmpu1ZiyvYD5VLGRn-us3Hkn06jce0VHh" rel="nofollow" target="_blank">here</a> to learn how to join our investigation and obtain additional information or contact us at <a href="https://www.globenewswire.com/Tracker?data=8UMWmk6-yDqO_o0cdnAEOF8LreIkC2QRzSZ4SArFVM_dXM7a78mEuY3GwKfmMFimGWeRkNzhLvCtfkDGSej6H6zf9yckz3H67tPGfPyjXDM=" rel="nofollow" target="_blank">gademi@ademilaw.com</a> or toll-free: 866-264-3995. There is no cost or obligation to you.</p> <p>Crinetics shareholders will receive $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. Crinetics insiders will http://www.streetinsider.com/Globe+Newswire/Shareholder+Alert%3A+Ademi+LLP+investigates+whether+Crinetics+Pharmaceuticals%2C+Inc.+is+obtaining+a+Fair+Price+for+Public+Shareholders/26792257.html Tue, 21 Jul 2026 07:37:44 -0400 CRNX http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Crinetics+Pharmaceutical+++++++++++++/26757330.html si-local-file:///var/storage/secattach/20260710/26757330.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Crinetics+Pharmaceutical+++++++++++++/26757330.html Fri, 10 Jul 2026 16:03:00 -0400 CRNX O.38517645 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Crinetics+Pharmaceutical+++++++++++++/26757330.html si-local-file:///var/storage/secattach/20260710/26757330.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Crinetics+Pharmaceutical+++++++++++++/26757330.html Fri, 10 Jul 2026 16:03:00 -0400 CRNX O.38517645 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Crinetics+Pharmaceutical++For%3A+Jul+06/26757306.html si-local-file:///var/storage/secattach/20260710/26757306.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Crinetics+Pharmaceutical++For%3A+Jul+06/26757306.html Fri, 10 Jul 2026 16:02:00 -0400 CRNX O.38517645 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Crinetics+Pharmaceutical++For%3A+Jul+06/26757306.html si-local-file:///var/storage/secattach/20260710/26757306.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Crinetics+Pharmaceutical++For%3A+Jul+06/26757306.html Fri, 10 Jul 2026 16:02:00 -0400 CRNX O.38517645 http://www.streetinsider.com/Downgrades/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html <p>Stifel analyst Alex Thompson downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold with a price target of $85.00 (from $83.00).</p><p>The analyst comments "We are downgrading CRNX to Hold from Buy and raising our target price to $85 from $83 following the proposed acquisition by VRTX (Hold, $522.25, covered by our colleague Paul Matteis) for ~$85/share (~$10B), announced earlier this week. As described in our previous note on the deal (LINK), we consider this to be a great outcome for CRNX/ shareholders. We see a high probability of the deal closing due to the lack of any clear overlap with VRTX's http://www.streetinsider.com/Downgrades/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html Wed, 08 Jul 2026 08:45:37 -0400 CRNX VRTX http://www.streetinsider.com/Downgrades/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html <p>Stifel analyst Alex Thompson downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold with a price target of $85.00 (from $83.00).</p><p>The analyst comments "We are downgrading CRNX to Hold from Buy and raising our target price to $85 from $83 following the proposed acquisition by VRTX (Hold, $522.25, covered by our colleague Paul Matteis) for ~$85/share (~$10B), announced earlier this week. As described in our previous note on the deal (LINK), we consider this to be a great outcome for CRNX/ shareholders. We see a high probability of the deal closing due to the lack of any clear overlap with VRTX's http://www.streetinsider.com/Downgrades/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html Wed, 08 Jul 2026 08:45:37 -0400 CRNX VRTX http://www.streetinsider.com/Analyst+PT+Change/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html <p>Stifel analyst Alex Thompson downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold with a price target of $85.00 (from $83.00).</p><p>The analyst comments "We are downgrading CRNX to Hold from Buy and raising our target price to $85 from $83 following the proposed acquisition by VRTX (Hold, $522.25, covered by our colleague Paul Matteis) for ~$85/share (~$10B), announced earlier this week. As described in our previous note on the deal (LINK), we consider this to be a great outcome for CRNX/ shareholders. We see a high probability of the deal closing due to the lack of any clear overlap with VRTX's http://www.streetinsider.com/Analyst+PT+Change/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html Wed, 08 Jul 2026 08:45:37 -0400 CRNX VRTX http://www.streetinsider.com/Analyst+PT+Change/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html <p>Stifel analyst Alex Thompson downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold with a price target of $85.00 (from $83.00).</p><p>The analyst comments "We are downgrading CRNX to Hold from Buy and raising our target price to $85 from $83 following the proposed acquisition by VRTX (Hold, $522.25, covered by our colleague Paul Matteis) for ~$85/share (~$10B), announced earlier this week. As described in our previous note on the deal (LINK), we consider this to be a great outcome for CRNX/ shareholders. We see a high probability of the deal closing due to the lack of any clear overlap with VRTX's http://www.streetinsider.com/Analyst+PT+Change/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html Wed, 08 Jul 2026 08:45:37 -0400 CRNX VRTX http://www.streetinsider.com/Analyst+Comments/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html <p>Stifel analyst Alex Thompson downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold with a price target of $85.00 (from $83.00).</p><p>The analyst comments "We are downgrading CRNX to Hold from Buy and raising our target price to $85 from $83 following the proposed acquisition by VRTX (Hold, $522.25, covered by our colleague Paul Matteis) for ~$85/share (~$10B), announced earlier this week. As described in our previous note on the deal (LINK), we consider this to be a great outcome for CRNX/ shareholders. We see a high probability of the deal closing due to the lack of any clear overlap with VRTX's http://www.streetinsider.com/Analyst+Comments/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html Wed, 08 Jul 2026 08:45:37 -0400 CRNX VRTX http://www.streetinsider.com/Analyst+Comments/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html <p>Stifel analyst Alex Thompson downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold with a price target of $85.00 (from $83.00).</p><p>The analyst comments "We are downgrading CRNX to Hold from Buy and raising our target price to $85 from $83 following the proposed acquisition by VRTX (Hold, $522.25, covered by our colleague Paul Matteis) for ~$85/share (~$10B), announced earlier this week. As described in our previous note on the deal (LINK), we consider this to be a great outcome for CRNX/ shareholders. We see a high probability of the deal closing due to the lack of any clear overlap with VRTX's http://www.streetinsider.com/Analyst+Comments/Stifel+Downgrades+Crinetics+%28CRNX%29+to+Hold/26744934.html Wed, 08 Jul 2026 08:45:37 -0400 CRNX VRTX http://www.streetinsider.com/Downgrades/Evercore+ISI+Downgrades+Crinetics+%28CRNX%29+to+In+Line/26743358.html <p>Evercore ISI analyst Gavin Clark-Gartner downgraded Crinetics (NASDAQ: CRNX) from Outperform to In Line with a price target of $85.00 (from $88.00).</p> <p>For an analyst ratings summary and ratings history on Crinetics <a href="http://www.streetinsider.com/rating_history.php?q=CRNX">click here</a>. For more ratings news on Crinetics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=CRNX&amp;type=analyst">click here</a>.</p> <p>Shares of Crinetics closed at $83.53 yesterday.</p> http://www.streetinsider.com/Downgrades/Evercore+ISI+Downgrades+Crinetics+%28CRNX%29+to+In+Line/26743358.html Wed, 08 Jul 2026 03:41:33 -0400 CRNX http://www.streetinsider.com/Analyst+PT+Change/Evercore+ISI+Downgrades+Crinetics+%28CRNX%29+to+In+Line/26743358.html <p>Evercore ISI analyst Gavin Clark-Gartner downgraded Crinetics (NASDAQ: CRNX) from Outperform to In Line with a price target of $85.00 (from $88.00).</p> <p>For an analyst ratings summary and ratings history on Crinetics <a href="http://www.streetinsider.com/rating_history.php?q=CRNX">click here</a>. For more ratings news on Crinetics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=CRNX&amp;type=analyst">click here</a>.</p> <p>Shares of Crinetics closed at $83.53 yesterday.</p> http://www.streetinsider.com/Analyst+PT+Change/Evercore+ISI+Downgrades+Crinetics+%28CRNX%29+to+In+Line/26743358.html Wed, 08 Jul 2026 03:41:33 -0400 CRNX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Crinetics+Pharmaceutical++For%3A+Jul+02++Filed+by%3A+Vivaldi+Coelho+Rogerio/26742171.html si-local-file:///var/storage/secattach/20260707/26742171.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Crinetics+Pharmaceutical++For%3A+Jul+02++Filed+by%3A+Vivaldi+Coelho+Rogerio/26742171.html Tue, 07 Jul 2026 16:31:00 -0400 CRNX O.38517645 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Crinetics+Pharmaceutical++For%3A+Jul+02++Filed+by%3A+Vivaldi+Coelho+Rogerio/26742171.html si-local-file:///var/storage/secattach/20260707/26742171.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Crinetics+Pharmaceutical++For%3A+Jul+02++Filed+by%3A+Vivaldi+Coelho+Rogerio/26742171.html Tue, 07 Jul 2026 16:31:00 -0400 CRNX O.38517645 http://www.streetinsider.com/Downgrades/TD+Cowen+Downgrades+Crinetics+%28CRNX%29+to+Hold/26741786.html <p>TD Cowen analyst Tyler Van Buren downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold.</p><p>For an analyst ratings summary and ratings history on Crinetics <a href="http://www.streetinsider.com/rating_history.php?q=CRNX">click here</a>. For more ratings news on Crinetics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=CRNX&amp;type=analyst">click here</a>.</p><p>Shares of Crinetics closed at $42.03 yesterday.</p> http://www.streetinsider.com/Downgrades/TD+Cowen+Downgrades+Crinetics+%28CRNX%29+to+Hold/26741786.html Tue, 07 Jul 2026 16:05:31 -0400 CRNX http://www.streetinsider.com/Downgrades/Citizens+Downgrades+Crinetics+%28CRNX%29+to+Market+Perform/26740855.html <p>Citizens analyst Jonathan Wolleben downgraded Crinetics (NASDAQ: CRNX) from Market Outperform to Market Perform.</p><p>For an analyst ratings summary and ratings history on Crinetics <a href="http://www.streetinsider.com/rating_history.php?q=CRNX">click here</a>. For more ratings news on Crinetics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=CRNX&amp;type=analyst">click here</a>.</p><p>Shares of Crinetics closed at $42.03 yesterday.</p> http://www.streetinsider.com/Downgrades/Citizens+Downgrades+Crinetics+%28CRNX%29+to+Market+Perform/26740855.html Tue, 07 Jul 2026 12:33:56 -0400 CRNX http://www.streetinsider.com/Downgrades/Jefferies+Downgrades+Crinetics+%28CRNX%29+to+Hold/26740051.html <p>Jefferies analyst Dennis Ding downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold.</p><p>For an analyst ratings summary and ratings history on Crinetics <a href="http://www.streetinsider.com/rating_history.php?q=CRNX">click here</a>. For more ratings news on Crinetics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=CRNX&amp;type=analyst">click here</a>.</p><p>Shares of Crinetics closed at $42.03 yesterday.</p> http://www.streetinsider.com/Downgrades/Jefferies+Downgrades+Crinetics+%28CRNX%29+to+Hold/26740051.html Tue, 07 Jul 2026 09:58:35 -0400 CRNX http://www.streetinsider.com/Downgrades/Jones+Trading+Downgrades+Crinetics+%28CRNX%29+to+Hold/26739866.html <p>Jones Trading analyst Catherine Novack downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold.</p><p>The analyst comments "What's new: Vertex (VRTX, Not Rated) announced an agreement to acquire Crinetics for $85/share in cash, implying an equity valuation of ~$10B or $8.8B net of estimated cash acquired(press release). Cash per-share price represents 102% premium to 7/6 closing price. We think the valuation is fair, and the press release notes the acquisition is expected to add ~$5B in revenues, which is consistent with our model estimates of $5.1B in peak revenues across paltusotine/atumelnant indications. The deal is expected to close in 3Q26. Upcoming catalysts: http://www.streetinsider.com/Downgrades/Jones+Trading+Downgrades+Crinetics+%28CRNX%29+to+Hold/26739866.html Tue, 07 Jul 2026 09:27:46 -0400 CRNX VRTX http://www.streetinsider.com/Downgrades/Jones+Trading+Downgrades+Crinetics+%28CRNX%29+to+Hold/26739866.html <p>Jones Trading analyst Catherine Novack downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold.</p><p>The analyst comments "What's new: Vertex (VRTX, Not Rated) announced an agreement to acquire Crinetics for $85/share in cash, implying an equity valuation of ~$10B or $8.8B net of estimated cash acquired(press release). Cash per-share price represents 102% premium to 7/6 closing price. We think the valuation is fair, and the press release notes the acquisition is expected to add ~$5B in revenues, which is consistent with our model estimates of $5.1B in peak revenues across paltusotine/atumelnant indications. The deal is expected to close in 3Q26. Upcoming catalysts: http://www.streetinsider.com/Downgrades/Jones+Trading+Downgrades+Crinetics+%28CRNX%29+to+Hold/26739866.html Tue, 07 Jul 2026 09:27:46 -0400 CRNX VRTX http://www.streetinsider.com/Analyst+Comments/Jones+Trading+Downgrades+Crinetics+%28CRNX%29+to+Hold/26739866.html <p>Jones Trading analyst Catherine Novack downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold.</p><p>The analyst comments "What's new: Vertex (VRTX, Not Rated) announced an agreement to acquire Crinetics for $85/share in cash, implying an equity valuation of ~$10B or $8.8B net of estimated cash acquired(press release). Cash per-share price represents 102% premium to 7/6 closing price. We think the valuation is fair, and the press release notes the acquisition is expected to add ~$5B in revenues, which is consistent with our model estimates of $5.1B in peak revenues across paltusotine/atumelnant indications. The deal is expected to close in 3Q26. Upcoming catalysts: http://www.streetinsider.com/Analyst+Comments/Jones+Trading+Downgrades+Crinetics+%28CRNX%29+to+Hold/26739866.html Tue, 07 Jul 2026 09:27:46 -0400 CRNX VRTX http://www.streetinsider.com/Analyst+Comments/Jones+Trading+Downgrades+Crinetics+%28CRNX%29+to+Hold/26739866.html <p>Jones Trading analyst Catherine Novack downgraded Crinetics (NASDAQ: CRNX) from Buy to Hold.</p><p>The analyst comments "What's new: Vertex (VRTX, Not Rated) announced an agreement to acquire Crinetics for $85/share in cash, implying an equity valuation of ~$10B or $8.8B net of estimated cash acquired(press release). Cash per-share price represents 102% premium to 7/6 closing price. We think the valuation is fair, and the press release notes the acquisition is expected to add ~$5B in revenues, which is consistent with our model estimates of $5.1B in peak revenues across paltusotine/atumelnant indications. The deal is expected to close in 3Q26. Upcoming catalysts: http://www.streetinsider.com/Analyst+Comments/Jones+Trading+Downgrades+Crinetics+%28CRNX%29+to+Hold/26739866.html Tue, 07 Jul 2026 09:27:46 -0400 CRNX VRTX